ReviewInternational journal of molecular sciences2026
How Physiology and Pharmacology Shape Liver Regeneration: From Molecules and Cells to Trials.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver regeneration is a tightly orchestrated compensatory response in which the remaining liver regains mass and function after liver injury or surgical resection. However, it does not fully restore its original anatomy. This process involves sequential priming, proliferative, and termination phases that are controlled by inflammatory cytokines, growth factor signaling, metabolic regulation, and extracellular matrix remodeling. Clinically, regenerative capacity plays a crucial role in situations such as partial hepatectomy, acute liver failure, and chronic liver disease. Unfortunately, it can be compromised by conditions like cirrhosis, steatosis, diabetes, and other systemic or local disorders. Current strategies to improve regeneration, such as portal vein modulation, cell-based therapies, organoid technology, and bioartificial liver support, show promise. However, they are limited by challenges including impaired engraftment, functional immaturity, technical complexity, and scalability restrictions. Against this background, the present review explores the pathophysiological basis of liver regeneration and evaluates the clinical evidence on nutritional and pharmacological interventions aimed at enhancing the natural liver repair mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.